Evidence map›Paper›PMID 36658421›Full record

ArticleNature medicine2023

Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.

Valeria Ricotti, Balasundaram Kadirvelu, Victoria Selby, Richard Festenstein, Eugenio Mercuri, Thomas Voit, A Aldo Faisal

Open access · hybridAbstract read
In one paragraph

Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Mechanomedicine.Nature reviews bioengineering · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Valeria Ricotti *National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre/University College London Great Ormond Street Institute of Child Health, London, UK.ORCID http://orcid.org/0000-0003-1800-1987
Balasundaram Kadirvelu *Brain & Behaviour Lab, Department of Bioengineering, Imperial College London, London, UK.
Victoria SelbyNational Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre/University College London Great Ormond Street Institute of Child Health, London, UK.
Richard FestensteinGene Control Mechanisms & Disease Group Department of Brain Sciences, Imperial College London, London, UK.
Eugenio MercuriUniversità Cattolica del Sacro Cuore, Rome, Italy.
Thomas VoitNational Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre/University College London Great Ormond Street Institute of Child Health, London, UK.ORCID http://orcid.org/0000-0002-7424-5401
A Aldo FaisalBrain & Behaviour Lab, Department of Bioengineering, Imperial College London, London, UK. aldo.faisal@imperial.ac.uk.ORCID http://orcid.org/0000-0003-0813-7207
Great Ormond Street Hospital · GBImperial College London · GBNIHR Imperial Biomedical Research Centre · GBUniversità Cattolica del Sacro Cuore · ITUniversity College Hospital · GB

Funding

Department of HealthMedical Research Council MC_EX_G0801765
6 · The paper itself

Abstract

Artificial intelligence has the potential to revolutionize healthcare, yet clinical trials in neurological diseases continue to rely on subjective, semiquantitative and motivation-dependent endpoints for drug development. To overcome this limitation, we collected a digital readout of whole-body movement behavior of patients with Duchenne muscular dystrophy (DMD) (n = 21) and age-matched controls (n = 17). Movement behavior was assessed while the participant engaged in everyday activities using a 17-sensor bodysuit during three clinical visits over the course of 12 months. We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls. Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.

Indexed as

Muscular Dystrophy, DuchenneWearable Electronic DevicesActivities of Daily LivingArtificial IntelligenceBayes TheoremBiomarkersCross-Sectional StudiesHumansBiomarkers

Identifiers

PMID36658421
PMCPMC9873561
OpenAlexW4317499915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.